Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-11-28

Clinical Trial Update: Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating sorafenib in patients with refractory non-small cell lung cancer has completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sorafenib (Sorafenib)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-11-28